Supplies and Logistics

Malaria medicines

In 2015, there were an estimated 214 million malaria cases and some 438 000 malaria deaths. Between 2000 and 2015, malaria incidence (the rate of new cases) fell by 37% globally. In the same period, malaria death rates fell by 60% globally among all age groups, and by 65% among children under 5.

A great proportion of the global malaria burden occurs in sub- Saharan Africa. In 2015, the region was home to 89% of malaria cases and 91% of malaria deaths.

In high-burden settings, malaria can trap families and communities in a downward spiral of poverty, disproportionately affecting marginalized and poor people who cannot afford treatment or who have limited access to health care.

In response to widespread resistance of Plasmodium falciparum to monotherapy with conventional antimalarial medicines such as Chloroquine and sulfadoxine-pyrimethamine, World Health Organization (WHO) now recommends combination therapies as treatment policy for falciparum malaria in all countries experiencing such resistance. Artemisinin-based combination therapies (ACTs) are the most highly efficacious treatment regimens available. See WHO treatment guidelines.

The following ACTs are currently recommended by WHO in its Treatment Guidelines (alphabetical order):

• Artemether-Lumefantrine,
• Artesunate + Amodiaquine,
• Artesunate + Mefloquine,
• Artesunate + Sulfadoxine–Pyrimethamine.
•Dihydroartemisinin + piperaquine

In 2013, ACTs had been adopted as national policy for first-line treatment in 79 of 87 countries where P. falciparum is endemic.

UNICEF and WHO conduct a joint annual tender for antimalarial medicines based on current WHO malaria treatment guidelines. Wherever possible UNICEF will procure products prequalified by the WHO Prequalification Programme. Where no or limited number of prequalified products are available, UNICEF and WHO will carry out a detailed technical evaluation of other antimalarial products available in the global market, in cooperation with relevant partners and regulatory agencies.

In 2014, UNICEF procured 14.6 million antimalaria treatments (artemisinin-based combination therapy — ACTs) and 9.9 million malaria rapid diagnostics tests (RDTs).

For more information on the malaria commodities available through UNICEF Supply Division, please visit the UNICEF supply catalogue

See more

WHO Global Malaria Programme:          
WHO guidelines for the treatment of malaria:
WHO antimalarial treatment policy by region:

World Malaria Report 2014:                  




UNICEF Supply Catalogue

New enhanced search